Skip to main content
. 2016 Apr 20;33(1):168–175. doi: 10.3904/kjim.2015.158

Figure 3.

Figure 3.

Overall survival of non-small cell lung cancer patients according to timing of brain metastases. Overall survival from the time of diagnosis of brain metastases (BM-OS) by epidermal growth factor receptor (EGFR) mutational status among patients with synchronous (A) or metachronous (B) development of brain metastases. EGFR mutant type (MT, dashed line) vs. EGFR (WT, solid line).